Aspects of PET imaging relevant to the assessment of striatal transplantation in Huntington's disease

Proper assessment of outcome in clinical trials of neural transplantation requires both biochemical and imaging indices of graft survival, and behavioural and physiological indices of graft function. For transplantation in Huntington's disease, a variety of ligands that are selective for striatal degeneration and graft‐derived replacement are available, notably ligands of dopaminergic receptors on striatal neurons. However, the validity of such ligands is potentially compromised by adjunctive drug therapies (e.g. neuroleptics) given to patients in the course of normal clinical care. We review the present state of experimental and clinical understanding of the selectivity of available ligands for striatal imaging, their interaction with other drug treatments, and strategies for refining valid assessment protocols in patients.

[1]  T. Jones,et al.  2D and 3D imaging of small animals and the human radial artery with a high resolution detector for PET , 1992 .

[2]  Antoine Geissbühler,et al.  2D And 3D Imaging Of Small Animals And The Human Radial Artery With A High Resolution Detector For PET , 1990, 1990 IEEE Nuclear Science Symposium Conference Record.

[3]  E. Ruzický,et al.  Stereotactic technique and pathophysiological mechanisms of neurotransplantation in Huntington's chorea. , 1992, Stereotactic and functional neurosurgery.

[4]  G. Sedvall,et al.  PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. , 1997, Brain : a journal of neurology.

[5]  T. Sharp,et al.  Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat , 1998, Psychopharmacology.

[6]  S. Stone-Elander,et al.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. , 1990, Archives of general psychiatry.

[7]  T. Reader,et al.  Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies , 1997, Neurochemistry International.

[8]  P Riederer,et al.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. , 1987, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[9]  R. M. Murray,et al.  Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia , 1992, The Lancet.

[10]  J. Arnt,et al.  Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence , 1998, Neuropsychopharmacology.

[11]  C D Marsden,et al.  Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. , 1990, Science.

[12]  M. Peschanski,et al.  Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease , 1995, Neuroscience.

[13]  E. Richfield,et al.  Heterogeneous dopamine receptor changes in early and late Huntington's disease , 1991, Neuroscience Letters.

[14]  L. Bäckman,et al.  Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. , 1997, Brain : a journal of neurology.

[15]  W. Martin,et al.  Cortical glucose metabolism in Huntington's disease , 1992, Neurology.

[16]  S. Folstein,et al.  Nigral dopamine type-1 receptors are reduced in Huntington's disease: A postmortem autoradiographic study using [3H]SCH 23390 and correlation with [3H]forskolin binding , 1990, Experimental Neurology.

[17]  C. Markham,et al.  Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease , 1984, Annals of neurology.

[18]  M. Hayden,et al.  Positron emission tomography in the early diagnosis of Huntington's disease , 1986, Neurology.

[19]  S B Dunnett,et al.  Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. , 1995, Neuroreport.

[20]  D. Brooks,et al.  Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.

[21]  C. Olanow,et al.  Neural transplantation as a therapy for Parkinson's disease. , 1997, Advances in neurology.

[22]  W. Galpern,et al.  In vivo PET Imaging in rat of dopamine terminals reveals functional neural transplants , 1998, Annals of neurology.

[23]  I. Creese,et al.  Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs. , 1997, The Journal of pharmacology and experimental therapeutics.

[24]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[25]  S. Jacques,et al.  Safety of Intrastriatal Neurotransplantation for Huntington's Disease Patients , 1998, Experimental Neurology.

[26]  J. Nobrega,et al.  Regional brain changes in [3H]SCH 23390 binding to dopamine D1 receptors after long-term haloperidol treatment: lack of correspondence with the development of vacuous chewing movements , 1998, Behavioural Brain Research.

[27]  B. Lipska,et al.  D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment , 1992, Brain Research.

[28]  D. Eidelberg,et al.  [11C]Raclopride‐PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length , 1998, Annals of neurology.

[29]  F. Ostrosky-solis,et al.  Fetal striatal homotransplantation for Huntington's disease: first two case reports. , 1995, Neurological research.

[30]  Adriaan A. Lammertsma,et al.  The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease , 1996, Journal of Neuroscience Methods.

[31]  R. Myers,et al.  Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography , 1992, Synapse.

[32]  P Boesiger,et al.  Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. , 1996, Brain : a journal of neurology.

[33]  S. Dunnett,et al.  The problem of antipsychotic treatment for functional imaging in Huntington's disease: receptor binding, gene expression and locomotor activity after sub-chronic administration and wash-out of haloperidol in the rat , 2000, Brain Research.

[34]  O. Lindvall.  Prospects of transplantation in human neurodegenerative diseases , 1991, Trends in Neurosciences.

[35]  O. Lindvall,et al.  Core assessment program for intracerebral transplantation in Huntington's disease (CAPIT‐HD) , 1996, Movement disorders : official journal of the Movement Disorder Society.

[36]  I. Creese,et al.  Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment , 1997, Neuroscience.

[37]  J C Mazziotta,et al.  Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease. , 1992, Archives of neurology.

[38]  M. Patterson,et al.  Fetal Transplantation for Huntington’s Disease: Clinical Studies , 1998 .

[39]  D. Brooks,et al.  Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. , 1995, Brain : a journal of neurology.

[40]  M. Rossor,et al.  Dopamine D-1 and D-2 receptors in Huntington's disease. , 1983, European journal of pharmacology.

[41]  M. Peschanski,et al.  Chapter 35 Prospectives for cell and gene therapy in Huntington's disease , 1998 .

[42]  V. Klimek,et al.  Chronic treatment with antidepressants decreases the number of [3H]SCH 23390 binding sites in the rat striatum and limbic system. , 1987, European journal of pharmacology.

[43]  E. Bird,et al.  Organization of dopamine D1 and D2 receptors in human striatum: Receptor autoradiographic studies in Huntington's disease and schizophrenia , 1988, Synapse.

[44]  Guy V. Sawle,et al.  The role of positron emission tomography in the assessment of human neurotransplantation , 1993, Trends in Neurosciences.

[45]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[46]  R Myers,et al.  The effects of donor stage on the survival and function of embryonic striatal grafts in the adult rat brain II. Correlation between positron emission tomography and reaching behaviour , 1997, Neuroscience.

[47]  C. Halldin,et al.  Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings. , 1997, Archives of general psychiatry.

[48]  P. Sanberg,et al.  Fetal-Tissue Transplantation for Huntington’s Disease: Preclinical Studies , 1998 .

[49]  K. Shannon,et al.  Neural Transplantation for Huntington's Disease: Experimental Rationale and Recommendations for Clinical Trials , 1996, Cell transplantation.

[50]  C. Olanow,et al.  Fetal nigral transplantation as a therapy for Parkinson's disease , 1996, Trends in Neurosciences.

[51]  S. Kapur,et al.  A new framework for investigating antipsychotic action in humans: lessons from PET imaging , 1998, Molecular Psychiatry.

[52]  L. Philpott,et al.  Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations. , 1997, Cell transplantation.

[53]  Y. Agid,et al.  Are cognitive changes the first symptoms of Huntington’s disease? A study of gene carriers , 1998, Journal of neurology, neurosurgery, and psychiatry.

[54]  R. Ridley,et al.  Functional integration of striatal allografts in a primate model of Huntington's disease , 1998, Nature Medicine.

[55]  O. Lindvall.  Neural transplantation: a hope for patients with Parkinson's disease , 1997, Neuroreport.

[56]  Björn Gustavii,et al.  Short‐ and long‐term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease , 1997, Annals of neurology.

[57]  A Weindl,et al.  Central motor processing in Huntington's disease. A PET study. , 1997, Brain : a journal of neurology.

[58]  P. Remy,et al.  MRI-Stereotactical Approach for Neural Grafting in Basal Ganglia Disorders , 1998, Experimental Neurology.